INTRODUCTION

This activity will feature a discussion by leading expert clinicians on new information about the treatment of myeloproliferative neoplasms (MPNs).

Launch Date: February 10, 2021
Release Date: February 10, 2021
Expiration Date: January 31, 2022

TARGET AUDIENCE

This program is intended for Medical Hematologist/Oncologists, Oncologists, Physician Assistants, Nurses and Nurse Practitioners who care for patients with myeloproliferative neoplasms.

OVERALL LEARNING OBJECTIVES

Upon completion of this enduring material, participants should be able to:

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CNE information.
• Review all modules associated with this course.
• Successfully complete the post-test ( accuracy).
• Complete the CME/CNE evaluation.
• The estimated time to complete this activity is hour.
• Upon successful completion, your CME/CNE certificate will be emailed to you.

ACCREDITATION STATEMENTS

Participation in the entire knowledge-based activity is required to obtain a certificate. This activity is being presented without bias and with commercial support.

RESOLUTION OF CONFLICT OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, Rush University Medical Center and Practice Point Communications will implement mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

DISCLOSURE

All planners and faculty participating in continuing education activities provided by the Rush University Medical Center are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. A commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the Rush University Medical Center.

The following speakers and/or planners have stated that they have the following financial relationship(s), and they have agreed to see that all information they planned and/or present is done so fairly and without bias:

DISCLOSURES

The speakers and planning committee members listed below have stated they have no significant relationships to disclose.
Mary Grantner
Melissa Larson, MD
Chris Fleming
Martin Stevens

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information they planned and/or present is done so fairly and without bias:

FACULTY DISCLOSURES

Dr. Srdan Verstovsek
Employment: Professor, Department of Leukemia, Division of Cancer Medicine, Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms, Chief, Section for Myeloproliferative Neoplasms, The University of Texas MD Anderson Cancer Center, Houston, TX
Industry Funded Research/investigator: AbbVie, Blueprint, BMS (Celgene), Constellation, CTI Biosciences, Gilead, Incyte, Ital Pharma, Kartos, Novartis, NS Pharma, Prelude Therapeutics, Promedior, Protagonist, Sierra Oncology
Consultant: None
Stock/Ownership: None
Patent holder: None
Other (please describe): None

Dr. Ruben A. Mesa
Employment: Director, Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
Industry Funded Research/investigator: Blueprint, Celgene , CTI Biopharma, Imago, Incyte, Sierra Oncology
Consultant: AbbVie, BMS, Imago, Novartis, Protagonist, Sierra Oncology
Speakers Bureau: None
Stock/Ownership: None
Patent holder: None
Other (please describe): None

Dr. John Mascarenhas
Employment: Associate Professor of Medicine, Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
Industry Funded Research/investigator: Arog, Forbius, Incyte, Merck, Merus, Novartis, PharmaEssentia, Promedior, Roche
Consultant: AbbVie, BMS (Celgene), CTI Biopharma, Roche
Stock/Ownership: None
Patent holder: None
Other (please describe): None

DISCLAIMER

The Rush University Medical Center and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center and Practice Point Communications assume no liability for the information herein.

PRIVACY POLICY

The Rush University Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.

Rush University Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

COPYRIGHT INFORMATION

Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:

The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.

HARDWARE/SOFTWARE REQUIREMENTS

• Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
• Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
• Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.

• Windows 7 or above running Internet Explorer 10 or above.
• MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
• A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.

• Any Apple iPad or iPad Mini running iOS 7.1 or above.
• Android tablets such as the Kindle Fire or Samsung Galaxy S.

COMMERCIAL SUPPORT ACKNOWLEDGMENT